The UAE has approved Tolebrutinib, the world’s first oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS). Developed to slow disability progression without relying on relapse control, it targets brain inflammation via B cells and microglia. This breakthrough highlights the Emirates Drug Establishment’s commitment to advancing neurological care and accelerating access to innovative, science-backed therapies.
